SecBot SecBot
SECBOTREPLAY Home › Report › IMNM

IMNM · Alliance Global Partners initiated coverage on Immunome Inc

Immunome Inc. · ANALYST-UPGRADE filed Sep 21, 2026 at 09:49 ET

At the news

BULLISHIMPACT 4/10

ANALYST-UPGRADE filed Sep 21, 2026 at 09:49 ET

Alliance Global Partners initiated coverage on Immunome Inc. (IMNM) with a Buy rating and a $32 price target, implying 33% upside from the current $23.97 close. The firm joins a heavily bullish consensus: 19 of 20 analysts rate IMNM Buy or Strong Buy, with only one Hold and no Sell ratings. The mean price target across 13 analysts is $36.31, with a high of $40 and a low of $30. Alliance Global's $32 target sits below the consensus mean and median, reflecting a more conservative stance relative to the Street. The firm's track record is below average, 41% accuracy on 92 calls with a -6.1% average return, which tempers the signal's weight. Over the past 30 days, analyst activity has been one upgrade and zero downgrades, though EPS revisions have been net negative: 7 downward revisions vs. 1 upward for the +1y period, and 10 downward vs. 0 upward for the current fiscal year. Insider selling has been notable, with CFO Isaac Barchas executing five sales totaling ~$2.9M in August and September 2026, including a $1.6M sale on August 11. Institutional activity is mixed: Citadel and Dimensional Fund Advisors more than doubled their positions, while JPMorgan and T. Rowe Price trimmed. Short interest stands at 57.7% of float, indicating elevated bearish positioning. The next earnings date is November 16, 2026, about 8 weeks out, so no near-term catalyst timing is in play. Bottom line: a new Buy initiation from a below-average-accuracy firm adds modest bullish coverage but is not a game-changer given the already crowded bullish consensus and persistent insider selling.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access